Richard Yeh & team
Citi
Richard Yeh, who guides the Citi duo up one notch to No. 2, provides “thorough, thoughtful and original analyses,” according to one investor. The researchers report on 16 companies and plan to increase that total to 20 within the year, the Hong Kong–based leader says, “as there has been a growing number of higher-quality companies and growing investor interest in the health care names.” The crew’s preferred picks this year include pharmaceuticals manufacturer China Medical System Holdings, which should enjoy strong product portfolio expansion from inlicensing arrangements — partnerships with one or more competitors to research, develop and/or distribute drugs — as well as its own development pipeline, Yeh explains. — Katie Gilbert